ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008233/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1),
compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic
Porphyrias (AHP).
提供机构：
Vivli
创建时间：
2022-07-06
